A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.

ABSTRACT:

Purpose

To examine the clinical utility of intratumor microRNAs (miRNA) as a biomarker for predicting responses to platinum-based doublet chemotherapy in patients with recurring lung adenocarcinoma (LADC).

Experimental design

The expression of miRNAs was examined in LADC tissues surgically resected from patients treated with platinum-based doublet chemotherapy at the time of LADC recurrence. Microarray-based screening of 904 miRNAs followed by quantitative reverse transcription-PCR-based verification in 40 test cohort samples, including 16 (40.0%) responders, was performed to identify miRNAs that are differentially expressed in chemotherapy responders and nonresponders. Differential expression was confirmed in a validation cohort (n = 63 samples), including 18 (28.6%) respon

SUBMITTER: Saito M 

PROVIDER: S-EPMC6329384 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature